Impact of Timing on the Functional Recovery Achieved With Platelet Supplementation After Treatment With Ticagrelor
Author(s) -
M. Urooj Zafar,
Donald A. Smith,
Usman Baber,
Samantha Sartori,
Kevin Chen,
David W. Lam,
Carlos Linares-Koloffon,
Juan Rey-Mendoza,
Gustavo Jiménez Brítez,
Ginés Escolar,
Valentı́n Fuster,
Juan J. Badimón
Publication year - 2017
Publication title -
circulation cardiovascular interventions
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.621
H-Index - 95
eISSN - 1941-7632
pISSN - 1941-7640
DOI - 10.1161/circinterventions.117.005120
Subject(s) - ticagrelor , medicine , aspirin , platelet , dosing , maintenance dose , loading dose , acute coronary syndrome , platelet transfusion , maintenance therapy , anesthesia , clopidogrel , cardiology , myocardial infarction , chemotherapy
American College of Cardiology/American Heart Association guidelines advise waiting 5 to 7 days before operating on P2Y 12 inhibitor-treated acute coronary syndrome patients, to allow dissipation of its antiplatelet effects. Platelet transfusion is often used to restore hemostasis during operations, but its effectiveness and optimal timing are unclear. We investigated the degree of functional gains obtained from platelet supplementation after loading and maintenance of dual antiplatelet therapy with ticagrelor and the influence of timing on this strategy.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom